Key Highlights

  • Definium is hosting an 8 AM EDT webcast today disclosing topline results from the Phase 3 Emerge study, the first randomised, double-blind, placebo-controlled trial of a single dose of DT120 ODT 100 µg in adults with major depressive disorder.
  • DT120 ODT (a pharmaceutical lysergide tartrate formulation) already holds FDA Breakthrough Therapy Designation for generalised anxiety disorder, with three Phase 3 studies expected to report this year across GAD and MDD.
  • DFTX is trading at $27.38 pre-market June 22, up 11.85% from the June 18 close of $24.48, with the broader healthcare ETF slightly lower, making Definium's move a standout catalyst-driven event.

A Phase 3 Readout Day for Psychedelic-Based MDD Therapy

Definium Therapeutics, Inc. (NASDAQ: DFTX), formerly known as Mind Medicine (MindMed) Inc., is trading at $27.38 pre-market June 22, up 11.85% from the June 18 close of $24.48. Definium is a New York-based late-stage clinical biopharmaceutical company developing next-generation psychedelic-based therapeutics targeting underlying causes of psychiatric and neurological disorders, with lead candidate DT120 ODT (lysergide tartrate) advanced across four Phase 3 trials in GAD and MDD.

The catalyst is today's 8 AM EDT webcast presenting topline results from the Emerge Phase 3 study, the first randomised, double-blind, placebo-controlled trial evaluating a single 100 µg dose of DT120 ODT in 149 adults with major depressive disorder. The primary endpoint is change from baseline in MADRS total score at Week 6. Investors are closely watching the readout, as Definium's DT120 programme has already demonstrated Breakthrough Therapy Designation status for anxiety, building foundational regulatory credibility for the broader psychiatric application. Three Phase 3 studies are expected to report this year, making 2026 a dense data year for the company.

The Ascend study, the second Phase 3 MDD trial, is structured with a low-dose arm designed to address functional unblinding concerns, reflecting Definium's proactive approach to FDA design guidance on psychedelic-based trials. The company holds approximately $411.6 million in cash as of Q4 2025, providing runway through the pivotal readout calendar.

Valuation and Risk Considerations

DFTX has a market capitalisation of $2.67 billion and a 52-week range of $12.88 to $26.15, with the pre-market session breaking above the prior range top. The primary risk is an adverse or inconclusive Emerge readout, which would reset the thesis. A positive result would validate the psychedelic-inspired medicine programme and create a direct path toward a regulatory submission.

Conclusion

Definium's pre-market advance is a textbook binary event trade: investors are positioning ahead of a same-day Phase 3 readout in a high-unmet-need indication with Breakthrough Therapy Designation precedent.